Evommune Secures $1.1 Billion License Deal for EVO570
Evommune has secured exclusive rights outside Greater China to develop EVO570 from Hinova Pharmaceuticals in…
Newswire
Alethio Secures $90M for Rare Blood Cancer Drug Development
Alethio has raised $90 million to develop a medicine targeting rare blood cancers, specifically myeloproliferative…
China’s Clinical Trials Face New Regulatory Challenges
In China, the landscape for clinical trials has shifted significantly due to new government regulations.…
PharmatrophiX and Circular Partner on Neurodegenerative Drugs
PharmatrophiX and Circular Genomics have partnered to advance blood-based circular RNA biomarkers in neurodegenerative drug…
CDMO Partnerships Evolve in Biopharma
David Enloe, CEO of Rose BioSolutions, argues that the traditional outsourcing model in biopharma is…
Lonza Expands U.S. CDMO Network with Merck KGaA Acquisition
Lonza plans to significantly expand its U.S. contract development and manufacturing organization (CDMO) footprint by…
Multiomic Atlas Reveals Predictable Patterns in Glioblastoma Cells
New research from the Wellcome Sanger Institute and collaborators reveals that aggressive glioblastoma (GB) brain…
Bernie Sanders to Influence FDA Funding Bill
Democrats’ recent electoral victory may significantly affect negotiations regarding the funding for the Food and…
FDA Workshop on Bioequivalence for Topical Generic Drugs
This half-day virtual workshop features FDA expert presentations and audience Q&A on bioequivalence (BE) approaches…
FDA Highlights Treatment Options for Opioid Use Disorder
The FDA has provided information regarding treatment options and therapies aimed at addressing opioid use…